Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Hogan

Internal Medicine Savannah, GA Medical Doctor

NPI 1265472823 CMS profile 284527

4425 Paulsen St, Bldg. A 1St Floor, Savannah, GA 31405

Open in the dashboard

General payments

$16,547

1,098 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Hogan of Savannah, GA is reported in the CMS Open Payments database as having received $16,547 across 1,098 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,701 152
2024 General $2,274 147
2023 General $2,824 173
2022 General $2,400 151
2021 General $2,105 135
2020 General $1,708 117
2019 General $2,536 223

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Hogan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thomas Hogan were reported at $2,701. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thomas Hogan Internal Medicine median Middle half National median
2019 $2,536 $159 $48–$570 $163
2020 $1,708 $119 $33–$402 $114
2021 $2,105 $135 $37–$521 $132
2022 $2,400 $141 $42–$496 $149
2023 $2,824 $149 $45–$519 $160
2024 $2,274 $154 $47–$537 $164
2025 $2,701 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,561 197 payments
  2. Pfizer Inc. $2,134 143 payments
  3. AbbVie, Inc. $1,664 106 payments
  4. Amgen Inc. $1,187 90 payments
  5. Lilly USA, LLC $1,064 81 payments
  6. AstraZeneca Pharmaceuticals LP $977 70 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $457 29 payments
  8. Astellas Pharma US Inc $449 26 payments
  9. Sanofi-Aventis U.S. LLC $429 23 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $416 25 payments
  11. Other $5,210 308 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,480 1,094 payments
  2. Education $67 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,564 125 payments
  2. RYBELSUS $1,238 100 payments
  3. NURTEC ODT $928 50 payments
  4. ELIQUIS $897 58 payments
  5. FARXIGA $895 64 payments
  6. UBRELVY $751 43 payments
  7. QULIPTA $676 38 payments
  8. Repatha $625 45 payments
  9. VRAYLAR $523 38 payments
  10. MOUNJARO $478 29 payments
  11. Other $14,086 957 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 201 drugs

Part D claims

20,049

Median for Internal Medicine: 777

Drug cost

$1,767,012

Median for Internal Medicine: $73,373

Branded share of claims

17.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 161 $271,835
Eliquis Apixaban Brand 215 $245,275
Jardiance Empagliflozin Brand 125 $162,010
Mounjaro Tirzepatide Brand 86 $105,602
Xarelto Rivaroxaban Brand 75 $97,181
Trulicity Dulaglutide Brand 61 $92,621
Januvia Sitagliptin Phosphate Brand 67 $92,590
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 73 $65,653
Rybelsus Semaglutide Brand 22 $60,783
Farxiga Dapagliflozin Propanediol Brand 45 $53,318

The 10 drugs with the highest cost, of 201 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$248,485

Of which drugs: $11,782

Medicare patients

787

Average age 76

Services billed

4,175

337 women, 450 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 22%
Chronic kidney disease 21%
Ischemic heart disease 20%
Atrial fibrillation 19%
Depression 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 22 22 $6,115
Vaccine for influenza for injection into muscle 90653 Office 66 66 $5,236

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
$207 — —
VRAYLAR
$175 — —
QULIPTA
$150 — —
ZEPBOUND
$148 — —
Wegovy
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

1,098 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record